Latest Commercialisation Milestones News

Green Critical Minerals has signed a landmark MoU with South Korea’s Komex Carbon Corporation to co-develop and commercialize Very High Density (VHD) carbon products, marking GCM’s first international commercial agreement and a key step toward revenue generation in 2026.

Altech Batteries has raised $6 million through a share placement to accelerate development and commercialisation of its innovative battery technologies, including the CERENERGY solid-state battery and Silumina Anodes.

Skin Elements Limited reported a 13% revenue increase and a 20% reduction in net loss for FY2025, as it progresses commercial roll-out of its natural biotech products including ECO-Nurture and SuprCuvr.

New Frontier Minerals reports exceptional assay results from its Harts Range Project, revealing high concentrations of heavy rare earth elements and niobium, setting the stage for its maiden drilling campaign and potential commercialisation.

Li-S Energy Limited reported a $6.41 million net loss for FY25 while making significant strides in commercialising its lithium-sulfur battery technology, including commissioning new production facilities and securing key strategic partnerships.

Carnegie Clean Energy launches a $3 million Share Purchase Plan at a 20% discount to fund its pioneering 6 MW CETO wave energy project in Spain and expand its global footprint.

Livium Ltd and Mineral Resources Ltd have formalised a 50 – 50 joint venture to commercialise the innovative LieNA® lithium processing technology, aiming to license it globally despite current market headwinds.

Hazer Group has successfully raised $10.7 million through a combination of a share placement and a share purchase plan, positioning the company to advance its innovative clean hydrogen and graphite production technology.

Altech Batteries Limited has made significant strides in funding and technology for its CERENERGY® battery project, including a $4 million capital raise and a breakthrough 55% increase in lithium-ion battery anode energy density.

Rhythm Biosciences reported a strong December quarter, securing a $3.2 million R&D tax incentive and completing a strategic acquisition of Genetype assets, positioning the company for commercial expansion in cancer diagnostics.